Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Candesartan Cilexetil

FDA-approved product (tablet, oral), marketed as Atacand, Candesartan Cilexetil.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Candesartan Cilexetil
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Congestive heart failure
  • Diabetes mellitus
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Stroke

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Angiotensin ii receptor blockers (arbs), plain
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli39.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae25.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Candesartan Cilexetil in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Candesartan Cilexetil with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Effects of Ramipril Combined With Candesartan

    NCT00356395 · start 2003-08

    Registered record
    Registry ID
    NCT00356395
    Conditions
    Hypertension
    Interventions
    ramipril, candesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2003-08
    Completion
    2006-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventionramipril, candesartan
    PhasePhase 4
    Registry statusCompleted

  • DIabetic Retinopathy Candesartan Trials.

    NCT00252720 · start 2001-08

    Registered record
    Registry ID
    NCT00252720
    Conditions
    Type 1 Diabetes
    Interventions
    candesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-08
    Completion
    2008-04
    Enrolment
    1,850

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 1 Diabetes
    Interventioncandesartan
    PhasePhase 3
    Registry statusCompleted

  • Danish Hypertension Prevention Project - DHYPP

    NCT00150631 · start 2000-11

    Registered record
    Registry ID
    NCT00150631
    Conditions
    Hypertension
    Interventions
    Candesartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2000-11
    Completion
    2014-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionCandesartan
    PhasePhase 3
    Registry statusUnknown

  • Genetic Epidemiology of Responses to Antihypertensives

    NCT00005520 · start 1997-02

    Registered record
    Registry ID
    NCT00005520
    Conditions
    Cardiovascular Diseases; Heart Diseases; Hypertension
    Interventions
    Hydrochlorothiazide; Candesartan
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1997-02
    Completion
    2008-01
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Heart Diseases; Hypertension
    InterventionHydrochlorothiazide; Candesartan
    PhaseNot recorded
    Registry statusCompleted

  • Study of Optimal Treatment Plan in Hypertensives With Anti-AT1-Receptor Autoantibody

    NCT00360763

    Registered record
    Registry ID
    NCT00360763
    Conditions
    Hypertension
    Interventions
    candesartan cilexetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    Not recorded
    Completion
    2006-12
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    Interventioncandesartan cilexetil
    PhasePhase 4
    Registry statusUnknown